PMC8009695

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and heart failure had a lower but statistically insignificant difference in pharmacy claims for ACE inhibitor/ARB therapy com

Effect: null; adjusted OR 0.87; CI: 95% CI = 0.76-1.003

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8